CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $49,763 | -22.8% | 1,096,354 | -4.5% | 0.08% | -18.3% |
| Q2 2023 | $64,445 | +23.2% | 1,147,929 | -0.8% | 0.10% | +14.3% |
| Q1 2023 | $52,323 | +8.3% | 1,156,810 | -2.7% | 0.09% | -6.2% |
| Q4 2022 | $48,305 | -99.9% | 1,188,321 | -4.6% | 0.10% | -41.2% |
| Q3 2022 | $81,374,000 | -4.1% | 1,245,199 | -10.8% | 0.16% | +5.1% |
| Q2 2022 | $84,850,000 | +4.7% | 1,396,258 | +8.2% | 0.16% | +45.4% |
| Q1 2022 | $81,030,000 | -18.8% | 1,290,905 | -1.9% | 0.11% | -10.7% |
| Q4 2021 | $99,736,000 | -3.8% | 1,316,123 | +42.1% | 0.12% | -4.7% |
| Q3 2021 | $103,638,000 | -29.5% | 925,914 | +1.9% | 0.13% | -28.7% |
| Q2 2021 | $147,101,000 | – | 908,652 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |